Abstract

Exponent, Inc. will release its quarterly results on July 30, 2026 Post Market, with current projections indicating mid-teens year-over-year growth in revenue and double-digit expansion in earnings metrics; this preview compiles the latest quarter’s reported figures, the company’s current-quarter forecasts, and recent analyst sentiment to frame catalysts and watchpoints.

Market Forecast

Consensus for the current quarter points to revenue of 147.55 million US dollars, up 12.78% year over year, earnings per share of 0.55, up 11.49% year over year, and EBIT of 36.96 million US dollars, up 13.06% year over year. Forecast detail for gross profit margin and net profit margin has not been issued, though the mix of billable activity and staff utilization will guide margin outcomes alongside the expected seasonal step-down from the prior quarter. The core Engineering and Other Scientific business is expected to remain the principal revenue driver this quarter as bill rate discipline and utilization support year-over-year growth, even as sequential activity normalizes from a strong first quarter base. Within this mix, Engineering and Other Scientific delivered 141.41 million US dollars last quarter and is positioned to contribute the bulk of the projected 147.55 million US dollars, while segment-level year-over-year figures were not disclosed.

Last Quarter Review

Exponent, Inc. reported revenue of 166.30 million US dollars, a gross profit margin of 39.79%, GAAP net income attributable to shareholders of 29.57 million US dollars, a net profit margin of 19.48%, and adjusted EPS of 0.59, up 13.46% year over year. A notable highlight was the sequential acceleration in net income, which rose 19.41% quarter over quarter, supported by strong top-line performance and cost discipline, while EPS exceeded external expectations. By business line, Engineering and Other Scientific contributed 141.41 million US dollars, and Environmental and Health contributed 24.89 million US dollars, with total revenue up 21.00% year over year on broad-based engagement growth and favorable case activity.

Current Quarter Outlook

Main business: Engineering and Other Scientific

The company’s main revenue engine is set to carry the quarter, even as seasonal patterns imply a sequential normalization from the first quarter’s peak delivery pace. The forecast for total revenue at 147.55 million US dollars, up 12.78% year over year, implies sustained demand for high-value advisory work and continued conversion of active engagements into billings. Within this framework, bill rates and utilization remain the two largest levers: modest pricing uplift on time-and-materials work can yield disproportionately positive operating leverage when paired with stable utilization, while any dip in utilization from elevated first-quarter levels may compress gross margin from its previously reported 39.79%. Operating expense cadence is another determinant of incremental profitability. The company’s forecast for EBIT at 36.96 million US dollars, up 13.06% year over year, signals confidence that overhead growth will remain contained relative to revenue, allowing for year-over-year operating margin stability or modest improvement even if gross margin moderates sequentially. Hiring, retention, and consultant mix will be closely watched, as an unfavorable pyramid or ramping cohort can elevate labor cost per billable hour. Conversely, a healthy pyramid with adequate leverage and accretive pricing should allow conversion of revenue growth into earnings with limited dilution to margin percentages. The last quarter’s segment revenue contribution of 141.41 million US dollars underscores how concentrated the company’s revenue is in this core franchise. Given that concentration, case timing and the share of reimbursable revenue represent important moving parts for margins. Lower reimbursables as a share of revenue typically support higher gross margin rates, while a higher mix can depress gross margin but has less effect on profit dollars. Management commentary around engagement starts, average matter duration, and client budgeting behavior will help investors refine estimates for the remainder of the year, particularly as the second quarter shapes the run rate for the back half.

Most promising business: Environmental and Health

Though smaller in absolute dollars at 24.89 million US dollars last quarter, Environmental and Health remains a meaningful contributor to diversification and can provide incremental growth through cross-practice collaboration and capacity deployment into active client mandates. Its scale relative to the core franchise means that incremental wins can translate into a visible percentage lift for the segment and a measurable, albeit smaller, impact on consolidated revenue. Because staffing in this segment can flex alongside demand, utilization management enables efficient scaling of delivery without structurally raising the cost base. Profit conversion within this segment should benefit from stable bill rates and targeted staffing that matches workload, reducing idle time and protecting margins. The absence of segment-level year-over-year disclosures limits precision in projecting its growth rate, but given the consolidated forecast indicating double-digit year-over-year expansion, the segment likely sustains positive momentum. For consolidated profitability, the blend of Environmental and Health work with the core franchise may support steady gross margin if the quarter’s mix contains a similar share of reimbursables and a stable case complexity profile versus the prior quarter. Communication about the pipeline and the balance between short-duration and multi-quarter matters will be important for assessing sustainability. Engagements that carry into subsequent periods enhance visibility and operating efficiency, while shorter-duration work tends to be sensitive to timing and can introduce variability. The company’s ability to channel staff from slower-moving tasks into areas of active demand mitigates this variability and supports margin preservation.

Key stock price drivers this quarter

The first swing factor is the degree to which the company can sustain the projected double-digit year-over-year growth against a strong comparative base. The prior quarter’s revenue grew 21.00% year over year to 166.30 million US dollars, creating a tougher comparison for the second quarter; meeting the 12.78% growth target would demonstrate healthy engagement conversion. Any commentary around bill rate increases and the pace of new matter intake will inform the trajectory for the second half of the year and may influence how investors recalibrate the forward run rate. The second factor is margin resilience as the revenue base steps down sequentially from the first quarter. The previously reported gross margin of 39.79% and net margin of 19.48% set a reference point; while sequential contraction is normal with seasonal volume changes, consolidation of operating expense efficiency and mix management can keep EBIT in line with the 36.96 million US dollars forecast and support the EPS goal of 0.55. Investors will parse the balance between permanent and variable costs, as well as any discrete items affecting the quarter, to distinguish core margin performance from transient effects. Capital allocation will be the third focal point for valuation framing this quarter. The recent update to the share repurchase authorization by an additional 50.00 million US dollars and the continuation of the quarterly dividend signal ongoing commitment to recurring shareholder returns. With average diluted shares outstanding trending down last quarter and the EPS estimate indicating 11.49% year-over-year growth, incremental buybacks could provide a tailwind to per-share metrics if executed at opportune levels. Taken together with stable operating performance, these capital returns can cushion valuation during periods of slower sequential growth and provide a bridge to the next acceleration phase if engagement intensity rises in subsequent quarters.

Analyst Opinions

Bullish views dominate among institutions tracking Exponent, Inc., with the average rating characterized as Buy and a mean price target around 90.00 US dollars. This constructive stance centers on the durability of mid-teens year-over-year growth in the current quarter (12.78% revenue growth and 11.49% EPS growth are projected) and the company’s demonstrated ability to translate utilization and bill-rate discipline into steady profitability. The latest quarter’s outperformance, including EPS of 0.59 up 13.46% year over year and consolidated revenue of 166.30 million US dollars up 21.00% year over year, reinforced confidence that the business can navigate seasonal fluctuations without compromising the full-year profit trajectory. Within this broadly positive backdrop, UBS maintained a Neutral view and trimmed its target to 75.00 US dollars, an outlier versus the higher mean target. The prevailing skew toward Buy ratings nonetheless reflects a belief that revenue growth above 10% and forecast EBIT expansion of 13.06% year over year this quarter provide sufficient operating momentum to meet or modestly exceed near-term expectations. Analysts emphasizing the bullish case also point to the updated share repurchase authorization of 50.00 million US dollars and the ongoing quarterly dividend as supportive of per-share earnings and return profiles, complementing organic growth in billable activity. The majority’s rationale focuses on three pillars of the upcoming print and guide. First, the projected revenue of 147.55 million US dollars this quarter indicates that underlying demand remains intact despite a normal seasonal step-down from the first quarter peak, which is consistent with the pattern embedded in the company’s historical cadence. Second, the EPS projection of 0.55 suggests operating leverage will hold as expense growth tracks below revenue and pricing remains firm, thereby containing margin dilution even if reimbursables or case mix drift. Third, capital allocation adds a layer of support to the equity story, particularly in a period when sequential trends could otherwise weigh on sentiment. Positive previews highlight the tight alignment between headcount growth and backlog conversion, with utilization expected to moderate from the first quarter yet remain within a range that sustains mid-to-high 30s gross margin on an annualized basis. While segment-level year-over-year growth rates were not disclosed, the concentration of revenue in Engineering and Other Scientific, which delivered 141.41 million US dollars last quarter, is viewed as an advantage so long as the company continues to manage staffing and case mix to protect profitability. The smaller Environmental and Health segment is seen as an incremental growth lever that can enhance diversification and help maintain stable aggregate margins. On balance, the weight of opinion anticipates that Exponent, Inc. will deliver results in line with or modestly ahead of the current-quarter forecasts, supported by operational discipline and a measured cost structure. Investors will watch qualitative commentary for indications about the pace of engagement starts and the pipeline into the second half, but the consensus view remains that mid-teens year-over-year growth in revenue and earnings is achievable this quarter, aligning with the provided estimates for revenue, EPS, and EBIT. As a result, bullish perspectives currently outweigh neutral or cautious stances, with emphasis on execution consistency and capital return as the key support factors for the equity into and beyond the July 30, 2026 Post Market event.